NeoAMR- Neonatal AntiMicrobial Resistance

NeoAMR is a research and development programme run by the Global Antibiotic R&D Partnership (GARDP), a joint initiative of DNDi and the WHO, which aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists. The overarching goal of NeoAMR is to develop new improved treatment regimens for the management of neonatal sepsis in settings with high prevalence of multidrug-resistant and extensively drug-resistant pathogens.  Penta is a partner in this project, leveraging its network and experience as a part of NeoAMR research activities.

To know more about the programme, read:

  • Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network the online article / PDF
  • Tackling antimicrobial resistance in neonatal sepsis the online article / PDF


As part of NeoAMR, GARDP launched the Global Neonatal Sepsis Observational Study (NeoOBS)  in July 2018. NeoOBS is a in collaboration between GARDP, St George’s University of London, Penta Foundation, University of Antwerp, MRC-Clinical trials Unit at University College London and 19 hospitals mainly in limited resource settings. The primary objective of NeoOBS is to assess mortality rates of hospitalised infants being treated with significant sepsis; secondary objectives include describing clinical presentation and recovery, sepsis management and microbiological epidemiology. This involved the collection of routine clinical, laboratory and antimicrobial therapy data from approximately 3000 neonates <60 days old with clinically diagnosed sepsis; patients were followed for 28 days. This global multi-centre prospective study has completed recruitment in February 2020 with each site having recruited up to 200 neonates. Data from the study will be used to inform the design of future antibiotic treatment trials for neonatal sepsis.

More details on specific activities can be found at:


We would like to update you on our recent activities